Use of aerosolized antithrombin to treat acute lung injury

• US 20050169908A1
• Filed: 01/13/2005
• Published: 08/04/2005
• Est. Priority Date: 01/23/2004
• Status: Abandoned Application

• Current Assignee: Board of Regents of the University of Texas System (University of Texas System), The University of Texas Medical Branch at Galveston (University of Texas System)
• Original Assignee: Board of Regents of the University of Texas System (University of Texas System)
• Inventors: Cox, Robert A., Hawkins, Hal A., Traber, Lillian D., Murakami, Kazunori, Traber, Daniel L., Enkhbaatar, Perenlei
• Application Number:
  US11/034,590
• Publication Number:
  US 20050169908A1
• Time in Patent Office: Days
• US Class Current: 424/94.640
• CPC Class Codes: A61K 38/57 from animals; from humans A61K38/553, A61K38/556 take precedence
• CPC Class Codes: A61P 11/00 Drugs for disorders of the respiratory system

Abstract

The invention features methods of treating a subject having a lung disorder such as lung inflammation and injury, by administering antithrombin III through pulmonary delivery.

Claims

1. A method of treating acute lung injury in a subject, comprising:

administering by inhalation a therapeutically effective amount of antithrombin III such that the lung injury is treated.

2. The method of claim 1, wherein the lung injury is septic acute lung injury.

3. The method of claim 1, wherein the lung injury is acute respiratory distress syndrome (ARDS).

4. The method of claim 1, wherein the lung injury is in response to exposure to a viral agent.

5. The method of claim 1, wherein the viral agent is Pseudomonas pneumonia.

6. The method of claim 1, wherein the lung injury is in response to one or more of smoke and asbestos.

7. The method of claim 1, wherein the antithrombin III is administered using an ultrasonic nebulizer.

8. The method of claim 1, wherein the antithrombin III is plasma derived antithrombin III.

9. The method of claim 1, wherein the antithrombin III is recombinantly produced antithrombin III.

10. The method of claim 9, wherein the recombinantly produced antithrombin III is transgenically produced antithrombin III.

11. The method of claim 1, wherein the subject is administered more than one dose of the antithrombin III.

12. The method of claim 1, wherein the antithrombin III is administered at a dose of about 10-300 U/kg of body weight.

13. The method of claim 1, wherein the antithrombin III is administered at a dose of about 25-125 U/kg of body weight.

14. The method of claim 1, wherein the lung injury is treated both with ATIII and argatroban.

15. The method of claim 1, wherein the lung injury treated was caused by smoke inhalation.

16. The method of claim 1, wherein the lung injury treated was caused by burn damage to the lungs.

17. A process for treating a human acute lung injury with a composition of matter containing a protein, said protein being encoded by a transgene DNA construct comprising ATIII.

18. A process for treating a human acute lung injury with a composition of matter containing a protein, said protein being encoded by a transgene DNA construct comprising ATIII, an improvement comprising treating a patient with a substantially pharmaceutically pure composition of said protein with an effective amount of argatroban.